Filippos Kesisoglou, PhD

Bio:

Filippos Kesisoglou is a Scientific Associate Vice President at Merck & Co., Inc., (Rahway, NJ, USA) Pharmaceutical Sciences department. Filippos has over 20 years of experience in the fields of biopharmaceutics and formulation development, pharmacokinetics and PBPK modeling as related to clinical, drug product development and CMC regulatory applications, including establishment of clinically relevant specifications,  across modalities. He has been a key contributor to several new drug applications across therapeutic areas. He has authored/co-authored 95 manuscripts/book chapters and more than 100 conference abstracts/podium presentations/webinars in several national/international meetings in the fields of biopharmaceutics, PBPK modeling, formulation development and drug delivery. Filippos has been involved over the years in several cross-industry and academia consortia including the IQ consortium and since 2023 has joined the ICH M13 (Bioequivalence Guideline) Expert Working Group. He is currently serving as an Editor for Journal of Pharmaceutical Sciences and on the Editorial Advisory Boards for the AAPS Journal and Pharmaceutical Research. He has been ellected a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and of the Americal Institute for Medical and Biological Engineering (AIMBE).